



A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 to 2009-2010

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004015
Article Type:	Research
Date Submitted by the Author:	12-Sep-2013
Complete List of Authors:	Liew, Gerald; Moorfields Eye Hospital, Medical Retina Michaelides, Michael; University College London, Bunce, Catey; University College London,
Primary Subject Heading:	Ophthalmology
Secondary Subject Heading:	Ophthalmology, Public health
Keywords:	Medical retina < OPHTHALMOLOGY, PUBLIC HEALTH, Diabetic retinopathy < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 to 2009-2010.

Short title: Blindness in England and Wales 2009-2010

Gerald Liew, Michel Michaelides, Catey Bunce

Moorfields Eye Hospital NHS Foundation Trust, London. EC1V 2PD, UK.
Gerald Liew, Medical Retina Research Fellow;
Michel Michaelides, Consultant Ophthalmologist.

Centre for Vision Research, Westmead Millenium Institute, University of Sydney, Sydney, Australia.
Gerald Liew, Honorary Senior Lecturer

Department of Genetics, University College London, Institute of Ophthalmology, Bath Street, London EC1V 9EL, UK;
Michel Michaelides, Clinical Senior Lecturer

National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology.
Catey Bunce, Senior Statistician

Financial Disclosure(s):

The authors have no proprietary or commercial interest in any materials discussed in this article.

Conflict of interest:

The authors have read and understood the BMJ Group policy on declaration of interests and declare no conflict of interest. All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that (1) No authors had support from any commercial companies for the submitted work; (2) GL received a fellowship from the Royal Australia New Zealand College of Ophthalmologists (RANZCO) Eye Foundation/Novartis scholarship for unrelated work during the period this report was written. No other authors have relationships with any companies that might have an interest in the submitted work in the previous 3 years; (3) No authors, their spouses, partners, or children have financial relationships that may be relevant to the submitted work; and (4) No authors have no non-financial interests that may be relevant to the submitted work.

Sources of Funding:

This study was supported by grants from the RNIB and the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The data captured by CVI are DH copyright and this work was made possible by collaboration with the Royal College of Ophthalmologists. The views expressed in this report are those of the authors and do not necessarily reflect those of the funding bodies. MM is a recipient of a Foundation Fighting Blindness Career Development Award.

Licensing

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and

1
2 media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store
3 the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include
4 within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other
5 derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the
6 inclusion of electronic links from the Contribution to third party material where-ever it may be located;
7 and, vi) licence any third party to do any or all of the above.
8
9
10

11 **Corresponding author:**

12 C. Bunce, Research and Development, Moorfields Eye Hospital, City Road, London EC1V2PD, UK
13 Tel: +442075662820
14 Fax: +442086086925
15 Email: c.bunce@ucl.ac.uk
16
17
18
19

20 Word count: 2367

21
22 Abstract: 233
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives. To report on the causes of blindness certifications in England and Wales in working age adults (16-64 years) in 2009-2010; and to compare these with figures from 1999-2000.

Design. Analysis of the national database of blindness certificates of vision impairment (CVIs) received by the Certifications Office.

Setting and Participants. Working age (16-64 years) population of England and Wales.

Main outcome measures. Number and cause of blindness certifications.

Results. The Certifications Office received 1756 CVIs for blindness from persons aged between 16 and 64 inclusive between 2009-2010. The main causes of blindness certifications were hereditary retinal disorders (354 certifications comprising 20.2% of the total), diabetic retinopathy/maculopathy (253 persons, 14.4%), and optic atrophy (248 persons, 14.1%). Together these three leading causes accounted for almost 50% of all blindness certifications. In 1999-2000, the leading causes of blindness certification were diabetic retinopathy/maculopathy (17.7%), hereditary retinal disorders (15.8%) and optic atrophy (10.1%).

Conclusions. For the first time in at least five decades, diabetic retinopathy/maculopathy is no longer the leading cause of certifiable blindness in England and Wales, having been overtaken by inherited retinal disorders. This change may be related to factors including the introduction of nationwide diabetic retinopathy screening programmes in England and Wales, and improved glycaemic control. Inherited retinal disease now representing the commonest cause of certification in the working age population has both clinical and research implications, including with respect to the provision of care/resources in the NHS and the allocation of research funding.

240 words

“Article Summary”

Article Focus.

- Blindness certifications are an important public health indicator in England and Wales.
- Every year, data on the number of persons certified blind is collected and the main causes listed.
- In 1999-2000, the leading causes of blindness certifications were diabetic retinopathy/maculopathy, hereditary retinal disorders and optic atrophy. We report results for 2009-2010.

Key messages.

- We report that for the first time in over five decades, diabetic retinopathy/maculopathy is no longer the leading cause of blindness in working age adults, having been overtaken by hereditary retinal disorders.
- This decline in blindness certifications from diabetic retinopathy/maculopathy may be related to the introduction of nationwide public health measures in England and Wales.
- The results have implications for resource allocations for clinical care delivery and research.

Strengths and Limitations

- Strengths of the data include nationwide coverage, collection of uniform data fields with pre-specified tick boxes, and clear and consistent definitions of sight impairment.
- Limitations include comparisons across two slightly different data collection forms.

Introduction

England and Wales have collected data on the number of blind people in the country since 1851.^{1,2} From 1930 until 2003, the causes of blindness have also been collected through use of a designated certificate, the BD8, which was completed by the examining ophthalmologist.² The BD8 was replaced in England in September 2005 by the Certificate of Vision Impairment (CVI), and in Wales in April 2007 by the equivalent form, the CVI-W. One copy of the CVI and CVI-W is then sent to the Certifications Office, London, for anonymised epidemiological analysis. The Certifications Office is currently funded by the RNIB (Royal National Institute for the Blind) and operates under the auspices of the Royal College of Ophthalmologists with CVI data under crown copyright.

Although not compulsory, certification allows patients to be registered (i.e. placed on an official local council register) as either severely sight impaired (blind) or sight impaired (partially sighted), which then permits access to certain state benefits and social service provisions. There is hence an incentive for patients to be certified and counted, providing an estimate, albeit imperfect,^{3,4} of the causes and burden of blindness in England and Wales. The importance of this data is highlighted by the fact that certification figures have recently been adopted in 2012 as an indicator for preventable sight loss and included in the Public Health Outcomes Framework.⁵ In this report we present the findings from an analysis of working age blindness certifications from 2009-2010 and compare these with figures from 1999-2000.⁶ Major changes in leading causes of blindness certification in this age group have occurred over this period; subsequent publications will report on findings in persons of other age groups.

Methods

Details of data entry, collections and transmission have been reported previously.⁶⁻⁸ For 2009-2010 data were obtained from CVI forms, whereas for 1999-2000, data were obtained from BD8 forms. With regards to CVI forms, data were transcribed from these paper-based forms into a database at the Certification Office. Part C of the CVI form collects information on the causes of visual loss and requires the completing ophthalmologist to select from a list of common diagnoses. More than one cause of visual loss can be

1 selected in which case the main cause should be highlighted using either an asterisk or circle. Guidelines are
2 provided to assist with this process when the main cause is not evident. 'Multiple' causes are used where
3 the ophthalmologist completing the form has not indicated a single main cause. Possible reasons for this
4 selection include differing causes in the two eyes, or more than one cause within one eye and the
5 ophthalmologist is unable to determine which contributes the most to the visual loss. Causes for visual
6 impairment were coded using International Classification of Diseases (ICD)-9 codes and grouped into
7 disease categories as in previous reports.⁶⁻⁸

8
9
10
11
12
13
14
15
16
17
18
19 For 1999-2000, data were extracted from paper based BD8 forms in a similar fashion.⁶ Part 5 of the BD8
20 form has 16 fields for medical information including one for the main cause of visual loss and five for each
21 eye for contributory causes. For records where the main cause was not filled, this field was imputed
22 wherever possible using an algorithm published previously.⁸ In short this algorithm brought forward as the
23 main cause the contributing cause if any were so listed; if more than one contributory cause was listed, the
24 patient was listed as having 'multiple causes'. The main difference between data collected from the CVI and
25 BD8 forms is the number of certifications with 'multiple causes' of visual impairment which was higher in
26 the CVI forms.⁷ We have previously minimized bias from this source by re-examining the certificates with
27 'multiple causes', extracting the contributory causes listed and tabulating them with the main causes.⁷ We
28 follow the same procedure in this report.

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43 Blindness was defined according to criteria previously described on the BD8 and CVI forms as either best
44 corrected visual acuity in the better eye of either (1) worse than 3/60, or (2) worse than 6/60 with severely
45 constricted visual fields, or (3) better than 6/60 with severely constricted visual fields particularly the
46 inferior field.

53 **Analyses**

54
55
56 Data regarding the main cause of visual impairment were extracted from the forms and grouped into
57 disease categories as previously described.⁶⁻⁸ For CVI data, those with 'multiple causes' or 'no information
58
59
60

1 on main cause' of visual impairment had contributory causes extracted and listed, and later combined with
2
3 the main causes. Pie and bar charts were used to graphically illustrate the distribution of the main causes of
4
5 visual impairment. Proportions of blindness registrations due to each cause are presented rather than
6
7 adjusted incidence rates in order to indicate the relative contribution of each condition to the pool of vision
8
9 impairment. Currently almost every grant application for diabetic retinopathy projects commences with a
10
11 statement that diabetic retinopathy is the most common cause of visual loss in the working age population
12
13 – we present proportions of blindness registrations to determine if this statement remains valid.
14
15
16
17
18
19

20 Results

21 For the period April 2009 to March 2010, the Certifications Office received 1756 CVIs for blindness from
22
23 persons aged between 16 and 64 inclusive. This compares with 1637 BD8 forms for blindness received
24
25 between April 1999 and March 2000, details of which have been reported previously.⁸ **Table 1** shows the
26
27 number of persons certified blind for each of the disease categories. Hereditary retinal disorders, including
28
29 Stargardt Disease and Retinitis Pigmentosa, formed the largest category with 354 certifications comprising
30
31 20.2% of the total. Diabetic retinopathy/maculopathy was the second largest cause of certifiable blindness
32
33 with 253 persons (14.4%), followed by optic atrophy with 248 persons (14.1%). Together these 3 leading
34
35 causes accounted for almost 50% of all blindness certifications in the working age group. Glaucoma was
36
37 responsible for 104 (5.9%) blindness certifications, followed by congenital abnormalities of the eye which
38
39 included congenital cataracts and retinopathy of prematurity (89 certifications, 5.1%). Multiple pathologies
40
41 were listed for 242 persons (13.8%) and no information on the main cause was listed for 42 persons (2.4%).
42
43 When these categories were examined for contributory causes, the most common contributory causes
44
45 recorded were glaucoma (60 persons), diabetic retinopathy/maculopathy (56 persons) and optic atrophy
46
47 (46 persons). Combining the main and contributory causes resulted in small changes in the overall
48
49 proportion of certifications due to specific causes, but did not change the relative rankings of the top six
50
51 causes of blindness (**Table 1**). 'Other conditions' comprised 150 certifications (8.5%) of which the most
52
53 common were malignant neoplasms of the brain and nervous system (27 persons, 1.5%) and retinal
54
55
56
57
58
59
60

1 detachments (24 persons, 1.4%). **Figure 1** shows the distribution of the causes of blindness certifications
2 graphically in a pie chart.
3
4

5
6
7
8 We next compared the main causes of blindness certifications from 1999-2000 (n=1637) with the figures
9 above from 2009-2010 (n=1756). The results are shown graphically in **Figure 2**. From 1999-2000, the
10 leading cause of blindness certification was diabetic retinopathy/maculopathy which accounted for 290
11 certifications (17.7%). By 2009-2010, this figure had decreased to 253 (14.4%), and diabetic
12 retinopathy/maculopathy was now the second leading cause of blindness certification. In contrast,
13 hereditary retinal disorders which were the second leading cause of blindness certification in 1999-2000
14 accounting for 258 cases (15.8% of total), had increased to 354 cases (20.2%) by 2009-2010 and have now
15 become the leading cause of certifiable blindness in the working age group in England and Wales. Optic
16 atrophy remained the third leading cause in 1999-2000 and 2009-2010 with an increase from 165 cases
17 (10.1%) to 248 cases (14.1%) respectively. A notable finding was that degeneration of the macula and
18 posterior pole, which accounted for 7.7% of blindness registration in 1999-2000, had dropped in
19 percentage terms and now accounted for only 3.0% by 2009-2010. Other causes of blindness registration
20 remained roughly similar for the two time periods.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 Discussion

39
40 This report provides updated estimates on the causes of certifiable blindness in England and Wales in
41 working age adults. Three main diseases were responsible for half of all certifications – hereditary retinal
42 disorders (20.2%), diabetic retinopathy/maculopathy (14.4%) and optic atrophy (14.1%). A marked change
43 has occurred in the relative importance of these main causes of blindness certifications since the last major
44 analysis in 1999-2000,⁶ with diabetic retinopathy/maculopathy now no longer the leading cause of
45 blindness in working age adults. Since at least 1963,⁹ diabetic retinopathy/maculopathy has been the
46 leading cause of blindness among working age adults in England and Wales; a similar situation exists in
47 other developed countries such as the United States.¹⁰ Over the past decade the proportion of
48
49
50
51
52
53
54
55
56
57
58
59
60

1 certifications for hereditary retinal disorders has slowly risen,⁸ while that for diabetic
2 retinopathy/maculopathy has reduced, resulting in the two conditions swapping rankings.
3
4

5
6
7
8 This report is not designed to identify the reasons behind these changes, but several intervening public
9 health developments may be contributory. Between 2003-2008 both England and Wales introduced
10 nationwide diabetic retinopathy screening services with the aim of reducing the incidence of blindness
11 from diabetic eye disease. These are known as the NHS Diabetic Eye Screening Program (England)¹¹ and
12 Diabetic Retinopathy Screening Service Wales (DRSSW)¹², and these programmes annually screen almost 2
13 million and 150,000 patients with diabetes, respectively. Concurrent with these screening programmes, in
14 2004 the Quality and Outcomes Framework¹³ was introduced to incentivise general practitioners in the
15 United Kingdom to improve primary care management of several conditions including diabetes. This effort
16 may have contributed to the improvement in glycaemic control documented since the late 1990s.^{13;14} The
17 decline in both the absolute number and relative proportion of blindness certifications due to diabetic
18 retinopathy/maculopathy since introduction of these public health measures may be an indicator of their
19 effectiveness.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 Whether increased rates of certification for inherited eye diseases reflects improved certification of existing
37 sight impairment, or a true increase in incidence of these disorders is unclear. The progress made over the
38 last decade in molecular genetics/diagnostics and the increasing avenues of research/clinical trials for
39 inherited retinal disease with widespread media coverage may plausibly have resulted in increasing clinic
40 visits and thereby registration,⁴ without a true increase in incidence rates. An observation in favour of this
41 scenario is that the rates of blindness certification for optic atrophy have also increased over the last
42 decade, in tandem with those for inherited retinal disease, while those for other non-inherited conditions
43 such as glaucoma have remained fairly constant. Hereditary retinal diseases occur more frequently in
44 communities with a higher rate of consanguinity, and it is conceivable that increased rates of immigration
45 from countries where consanguinity is more prevalent may have contributed to these findings, though at
46 this stage this remains speculative.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 These findings have implications for clinical care and research budget allocation. A prolonged focus on
5
6 prevention and treatment of diabetic eye disease has likely contributed to the decline in blindness
7
8 certifications from this disorder, and the rate is expected to decline further with the recent National
9
10 Institute for Clinical Excellence (NICE) approval of ranibizumab for treatment of diabetic maculopathy. Now
11
12 that hereditary retinal diseases comprise the leading cause of blindness certifications, an increased focus
13
14 on clinical management of these conditions (e.g. with low vision aids, visual rehabilitation) and greater
15
16 allocation of research funding to study these disorders may be appropriate. Funding bodies may need to re-
17
18 asses their funding priorities.
19

20 21 22 23 **Strengths and Limitations**

24
25 Data from BD8 and CVI registrations represent some of the best available epidemiological data on sight
26
27 impairment in England and Wales and is regarded as a major public health indicator.⁵ Strengths of the data
28
29 include nationwide coverage, collection of uniform data fields with pre-specified tick boxes, and clear and
30
31 consistent definitions of sight impairment.
32

33
34
35
36 Limitations that should be highlighted include that fact that blindness certifications are not equivalent to
37
38 blindness rates. This has been discussed previously^{3,4} and it is estimated that up to 53% of eligible patients
39
40 may not be registered blind despite consultation with an ophthalmologist.⁷ However, arguments have been
41
42 advanced that in time, most patients eligible to be registered will in fact do so,⁷ and studies have shown a
43
44 major increase in registration rates with increasing clinic visits.⁴
45
46
47
48

49
50 Another caveat to these results is that some patients who are certified blind may not always satisfy all of
51
52 the official criteria, with one study suggesting an inappropriate blindness certification rate of 23%.³ Such
53
54 inappropriate certifications may inflate the numbers somewhat but it should be borne in mind that the aim
55
56 of certification is not to identify persons meeting rigid clinical criteria but to identify and count those with
57
58 significant visual impairment who may benefit from state assistance. Indeed, current guidelines for
59
60

1 completion of CVI forms state that the criteria should be interpreted in the context of the patient's
2 functional status rather than as strict cut-offs. Another caveat when interpreting these results is that the
3 figures for the two time periods were collated from different forms. The differences in these forms are
4 discussed elsewhere⁷ and one of the main complications in comparing temporal trends is the increase in
5 the number of forms where a main cause has not been identified. In the 1999-2000 dataset, which was
6 derived from BD8, approximately 4% of forms had 'multiple pathology'; in the 2009-2010 dataset derived
7 from CVI, this had increased to 14%. This raised the possibility that diabetic retinopathy/maculopathy may
8 have been under-reported for the 2009-2010 period. We attempted to address this by examining the
9 contributory causes in those without a main cause recorded and using these in place of the missing main
10 cause; this analysis resulted in only small changes to the percentage of blindness due to each cause and did
11 not change the overall ranking of the top six causes. This suggests that the rate of under-reporting of main
12 causes was similar for most categories and not responsible for the shift in the leading causes of blindness
13 certifications.

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32 In summary, this report found three main causes were responsible for half of all blindness certifications
33 among working age adults in England and Wales from 2009-2010 - hereditary retinal disorders (20.2%),
34 followed by diabetic retinopathy/maculopathy (14.4%) and optic atrophy (14.1%). This marks the first time
35 in almost five decades that diabetic retinopathy/maculopathy is no longer the leading cause of blindness in
36 working age adults, and may be related to the introduction of nationwide public health measures in
37 England and Wales. The results have implications for resource allocations for clinical care delivery and
38 research.

Table 1. Numbers of working age adults (age 16-64) with severe sight impairment (blindness) in England and Wales: certifications 2009-2010. The 'Main cause' column lists the number of certifications with the corresponding diagnosis; the 'Contributory cause' column lists the contributory causes in certifications from the 'Multiple pathology' and 'No Information on main cause' categories.

ICD-9 Codes	Diagnosis	Main cause (% Total)	Contributory cause (% Total)	Combined (% Total)
362.7	Hereditary retinal disorders	354 (20.2)	29 (6.6)	383 (20.0)
362/34000	Diabetic retinopathy/maculopathy	253 (14.4)	56 (12.8)	309 (16.2)
377.1	Optic atrophy	248 (14.1)	46 (10.5)	294 (15.4)
365	Glaucoma	104 (5.9)	60 (13.7)	164 (8.6)
743-760	Congenital abnormalities of the eye	89 (5.1)	32 (7.3)	121 (6.3)
377.7	Disorders of visual cortex	72 (4.1)	24 (5.5)	96 (5.0)
430-438	Cerebrovascular disease	56 (3.2)	21 (4.8)	77 (4.0)
362.5	Degeneration of macula and posterior pole	52 (3.0)	14 (3.2)	66 (3.5)
360.2	Myopia	49 (2.8)	23 (5.2)	72 (3.8)
370-371	Corneal disorders	45 (2.6)	34 (7.7)	79 (4.1)
-	Multiple pathology	242 (13.8)	-	-
-	Other conditions	150 (8.5)	100 (22.8)	250 (13.1)
-	No information on main cause	42 (2.4)	-	-
Total		1756	439*	1911*

ICD refers to International Classification of Disease.

*Including contributory causes. The total number of contributory causes is greater than the sum of 'Multiple pathology' and 'No information on main cause' categories because persons can have between one and four contributory causes documented.

Figure 1. Main causes of severe sight impairment (blindness) in England and Wales in working age adults (age 16-64): certifications 2009-2010.





Figure 2. 10-year change in causes of severe sight impairment (blindness) in England and Wales in working age adults (age 16-64): certifications 1999-2000 and 2009-2010.

Change in Main Causes of Blindness Certification from 2000 to 2010



BMJ

Reference List

- 1
2
3
4 (1) Sorsby A. The causes of blindness in England 1948-50. 1953. London, HMSO.
- 5
6 (2) Sorsby A. The incidence and causes of blindness in England and Wales 1948-1962. 1-78. 1966.
7 London, HM Stationery Office. Reports on Public Health and Medical Subjects No. 114.
- 8
9 (3) Barry RJ, Murray PI. Unregistered visual impairment: is registration a failing system? Br J
10 Ophthalmol 2005; 89(8):995-998.
- 11
12 (4) Robinson R, Deutsch J, Jones HS, Youngson-Reilly S, Hamlin DM, Dhurjon L et al. Unrecognised and
13 unregistered visual impairment. Br J Ophthalmol 1994; 78(10):736-740.
- 14
15 (5) UK Department of Health. Healthy Lives, Healthy People: Improving Outcomes and Supporting
16 Transparency. 2012.
- 17
18 (6) Bunce C, Wormald R. Causes of blind certifications in England and Wales: April 1999-March 2000.
19 Eye (Lond) 2008; 22(7):905-911.
- 20
21 (7) Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England &
22 Wales. BMC Public Health 2006; 6:58.
- 23
24 (8) Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales:
25 April 2007-March 2008. Eye (Lond) 2010; 24(11):1692-1699.
- 26
27 (9) Sorsby A. The incidence and causes of blindness in England and Wales 1963-1968. 1972. London,
28 HM Stationary Office. DHSS reports on public health and medical subjects No 128.
- 29
30 (10) Centers for Disease Control and Prevention. http://www.cdc.gov/visionhealth/basic_information/eye_disorders.htm [2013 [cited 2013 July 20];
- 31
32 (11) NHS Diabetic Eye Screening Programme. <http://diabeticeye.screening.nhs.uk/about> [2013
- 33
34 (12) Diabetic Retinopathy Screening Service Wales. <http://www.cardiffandvaleuhb.wales.nhs.uk/drssw> [
35 2013
- 36
37 (13) Calvert M, Shankar A, McManus RJ, Lester H, Freemantle N. Effect of the quality and outcomes
38 framework on diabetes care in the United Kingdom: retrospective cohort study. BMJ 2009;
39 338:b1870.
- 40
41 (14) Oluwatowoju I, Abu E, Wild SH, Byrne CD. Improvements in glycaemic control and cholesterol
42 concentrations associated with the Quality and Outcomes Framework: a regional 2-year audit of
43 diabetes care in the UK. Diabet Med 2010; 27(3):354-359.
- 44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract Y	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale Y	2	Explain the scientific background and rationale for the investigation being reported
Objectives Y	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design Y	4	Present key elements of study design early in the paper
Setting Y	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants Y	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables Y	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement Y	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias Y	9	Describe any efforts to address potential sources of bias
Study size NA	10	Explain how the study size was arrived at
Quantitative variables NA	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods Y	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(e) Describe any sensitivity analyses

Continued on next page

For peer review only

Results

Participants Y	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data Y	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data Y	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results Y	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses Y	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results Y	18	Summarise key results with reference to study objectives
Limitations Y	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation Y	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability Y	21	Discuss the generalisability (external validity) of the study results

Other information

Funding Y	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
--------------	----	---

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.



A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004015.R1
Article Type:	Research
Date Submitted by the Author:	05-Dec-2013
Complete List of Authors:	Liew, Gerald; Moorfields Eye Hospital, Medical Retina Michaelides, Michael; University College London, Bunce, Catey; University College London,
Primary Subject Heading:	Ophthalmology
Secondary Subject Heading:	Ophthalmology, Public health
Keywords:	Medical retina < OPHTHALMOLOGY, PUBLIC HEALTH, Diabetic retinopathy < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts

1
2 **A comparison of the causes of blindness certifications in England and Wales in working**
3
4 **age adults (16-64 years), 1999-2000 with 2009-2010**

5
6 Short title: Blindness in England and Wales 2009/2010

7
8 Gerald Liew, Michel Michaelides*, Catey Bunce*

9
10
11 Moorfields Eye Hospital NHS Foundation Trust, London. EC1V 2PD, UK.

12 Gerald Liew, Medical Retina Research Fellow;
13 Michel Michaelides, Consultant Ophthalmologist.

14
15
16 Centre for Vision Research, Westmead Millenium Institute, University of Sydney, Sydney, Australia.

17 Gerald Liew, Honorary Senior Lecturer

18
19 Department of Genetics, University College London, Institute of Ophthalmology, Bath Street, London EC1V
20 9EL, UK;

21 Michel Michaelides, Clinical Senior Lecturer

22
23 National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS
24 Foundation Trust and UCL Institute of Ophthalmology.

25 Catey Bunce, Senior Statistician
26
27

28 **Corresponding authors:**

29 C. Bunce, Research and Development, Moorfields Eye Hospital, City Road, London EC1V2PD, UK

30 Tel: +442075662820

31 Fax: +442086086925

32 Email: c.bunce@ucl.ac.uk
33
34

35 M. Michaelides, Department of Genetics, University College London, Institute of Ophthalmology, Bath
36 Street, London EC1V 9EL, UK

37 Tel: +442076086864

38 Email: michel.michaelides@ucl.ac.uk
39

40 Word count: 2367
41
42

43 Abstract: 233
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives. To report on the causes of blindness certifications in England and Wales in working age adults (16-64 years) in 2009-2010; and to compare these with figures from 1999-2000.

Design. Analysis of the national database of blindness certificates of vision impairment (CVIs) received by the Certifications Office.

Setting and Participants. Working age (16-64 years) population of England and Wales.

Main outcome measures. Number and cause of blindness certifications.

Results. The Certifications Office received 1756 CVIs for blindness from persons aged between 16 and 64 inclusive between 1st April 2009 to 31st March 2010. The main causes of blindness certifications were hereditary retinal disorders (354 certifications comprising 20.2% of the total), diabetic retinopathy/maculopathy (253 persons, 14.4%), and optic atrophy (248 persons, 14.1%). Together these three leading causes accounted for almost 50% of all blindness certifications. Between 1st April 1999 to 31st March 2000, the leading causes of blindness certification were diabetic retinopathy/maculopathy (17.7%), hereditary retinal disorders (15.8%) and optic atrophy (10.1%).

Conclusions. For the first time in at least five decades, diabetic retinopathy/maculopathy is no longer the leading cause of certifiable blindness amongst working age adults in England and Wales, having been overtaken by inherited retinal disorders. This change may be related to factors including the introduction of nationwide diabetic retinopathy screening programmes in England and Wales, and improved glycaemic control. Inherited retinal disease now representing the commonest cause of certification in the working age population has both clinical and research implications, including with respect to the provision of care/resources in the NHS and the allocation of research funding.

240 words

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

“Article Summary”

Article Focus.

- Blindness certifications are an important public health indicator in England and Wales.
- Every year, data on the number of persons certified blind is collected and the main causes listed.
- In 1999-2000, the leading causes of blindness certifications were diabetic retinopathy/maculopathy, hereditary retinal disorders and optic atrophy. We report results for 2009-2010.

Key messages.

- We report that for the first time in over five decades, diabetic retinopathy/maculopathy is no longer the leading cause of blindness in working age adults, having been overtaken by hereditary retinal disorders.
- This decline in blindness certifications from diabetic retinopathy/maculopathy may be related to the introduction of nationwide public health measures in England and Wales.
- The results have implications for resource allocations for clinical care delivery and research.

Strengths and Limitations

- Strengths of the data include nationwide coverage, collection of uniform data fields with pre-specified tick boxes, and clear and consistent definitions of sight impairment.
- Limitations include comparisons across two slightly different data collection forms.

Introduction

England and Wales have collected data on the number of blind people in the country since 1851.^{1,2} From 1930 until 2003, the causes of blindness have also been collected through use of a designated certificate, the BD8, which was completed by the examining ophthalmologist.² The BD8 was replaced in England in September 2005 by the Certificate of Vision Impairment (CVI), and in Wales in April 2007 by the equivalent form, the CVI-W. One copy of the CVI and CVI-W is then sent to the Certifications Office, London, for anonymised epidemiological analysis. The Certifications Office is currently funded by the RNIB (Royal National Institute for the Blind) and operates under the auspices of the Royal College of Ophthalmologists with CVI data under Crown copyright, meaning the copyright is owned by the British Government.

Although not compulsory, certification allows patients to be registered (i.e. placed on an official local council register) as either severely sight impaired (blind) or sight impaired (partially sighted), which then permits access to certain state benefits and social service provisions. There is hence an incentive for patients to be certified and counted, providing an estimate, albeit imperfect,^{3,4} of the causes and burden of blindness in England and Wales. The importance of these data is highlighted by the fact that certification figures have recently been adopted in 2012 as an indicator for preventable sight loss and included in the Public Health Outcomes Framework.⁵ In this report we present the findings from an analysis of working age blindness certifications from 2009-2010 and compare these with figures from 1999-2000.⁶ Major changes in leading causes of blindness certification in this age group have occurred over this period; subsequent publications will report on findings in persons of other age groups.

Methods

Details of data entry, collections and transmission have been reported previously.⁶⁻⁸ Between 1st April 2009 to 31st March 2010 data were obtained from CVI forms, whereas between 1st April 1999 to 31st March 2000, data were obtained from BD8 forms. With regards to CVI forms, data were transcribed from these paper-based forms into a database at the Certification Office. Part C of the CVI form collects information on the causes of visual loss and requires the completing ophthalmologist to select from a list of common

1 diagnoses. More than one cause of visual loss can be selected in which case the main cause should be
2 highlighted using either an asterisk or circle. Guidelines are provided to assist with this process when the
3 main cause is not evident. 'Multiple' causes are used where the ophthalmologist completing the form has
4 not indicated a single main cause. Possible reasons for this selection include differing causes in the two
5 eyes, or more than one cause within one eye and the ophthalmologist is unable to determine which
6 contributes the most to the visual loss. Causes for visual impairment were coded using International
7 Classification of Diseases (ICD)-9 codes and grouped into disease categories as in previous reports.⁶⁻⁸

8
9
10
11
12
13
14
15
16
17
18
19 For 1999-2000, data were extracted from paper based BD8 forms in a similar fashion.⁶ Part 5 of the BD8
20 form has 16 fields for medical information including one for the main cause of visual loss and five for each
21 eye for contributory causes. For records where the main cause was not filled, this field was imputed
22 wherever possible using an algorithm published previously.⁸ In short this algorithm brought forward as the
23 main cause the contributing cause if any were so listed; if more than one contributory cause was listed, the
24 patient was listed as having 'multiple causes'. The main difference between data collected from the CVI and
25 BD8 forms is the number of certifications with 'multiple causes' of visual impairment which was higher in
26 the CVI forms.⁷ We have previously minimized bias from this source by re-examining the certificates with
27 'multiple causes', extracting the contributory causes listed and tabulating them with the main causes.⁷ We
28 follow the same procedure in this report.

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43 Blindness was defined according to criteria previously described on the BD8 and CVI forms as either best
44 corrected visual acuity in the better eye of either (1) worse than 3/60, or (2) worse than 6/60 with severely
45 constricted visual fields, or (3) better than 6/60 with severely constricted visual fields particularly the
46 inferior field.

47 48 49 50 51 52 53 **Analyses**

54
55
56 Data regarding the main cause of visual impairment were extracted from the forms and grouped into
57 disease categories as previously described.⁶⁻⁸ For CVI data, those with 'multiple causes' or 'no information
58
59
60

1 on main cause' of visual impairment had contributory causes extracted and listed, and later combined with
2 the main causes. Pie and bar charts were used to graphically illustrate the distribution of the main causes of
3 visual impairment. Proportions of blindness registrations due to each cause are presented rather than
4 adjusted incidence rates in order to indicate the relative contribution of each condition to the pool of vision
5 impairment. Currently almost every grant application for diabetic retinopathy projects commences with a
6 statement that diabetic retinopathy is the most common cause of visual loss in the working age population
7 – we present proportions of blindness registrations to determine if this statement remains valid. X^2 tests
8 were performed to test differences in proportions.
9
10
11
12
13
14
15
16
17
18
19
20

21 Results

22 For the period 1st April 2009 to 31st March 2010, the Certifications Office received 1756 CVIs for blindness
23 from persons aged between 16 and 64 inclusive. This compares with 1637 BD8 forms for blindness received
24 between 1st April 1999 and 31st March 2000, details of which have been reported previously.⁸ **Table 1**
25 shows the number of persons certified blind for each of the disease categories. Hereditary retinal
26 disorders, including Stargardt Disease and Retinitis Pigmentosa, formed the largest category with 354
27 certifications comprising 20.2% of the total. Diabetic retinopathy/maculopathy was the second largest
28 cause of certifiable blindness with 253 persons (14.4%), followed by optic atrophy with 248 persons
29 (14.1%). Together these 3 leading causes accounted for almost 50% of all blindness certifications in the
30 working age group. Glaucoma was responsible for 104 (5.9%) blindness certifications, followed by
31 congenital abnormalities of the eye which included congenital cataracts and retinopathy of prematurity (89
32 certifications, 5.1%). Multiple pathologies were listed for 242 persons (13.8%) and no information on the
33 main cause was listed for 42 persons (2.4%). When these categories were examined for contributory
34 causes, the most common contributory causes recorded were glaucoma (60 persons), diabetic
35 retinopathy/maculopathy (56 persons) and optic atrophy (46 persons). Combining the main and
36 contributory causes resulted in small changes in the overall proportion of certifications due to specific
37 causes, but did not change the relative rankings of the top six causes of blindness (**Table 1**). 'Other
38 conditions' comprised 150 certifications (8.5%) of which the most common were malignant neoplasms of
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 the brain and nervous system (27 persons, 1.5%) and retinal detachments (24 persons, 1.4%). **Figure 1**
2 shows the distribution of the causes of blindness certifications graphically in a pie chart.
3
4
5
6
7

8 We next compared the main causes of blindness certifications from 1999-2000 (n=1637) with the figures
9 above from 2009-2010 (n=1756). The results are shown graphically in **Figure 2**. From 1999-2000, the
10 leading cause of blindness certification was diabetic retinopathy/maculopathy which accounted for 290
11 certifications (17.7%). By 2009-2010, this figure had decreased to 253 (14.4%), and diabetic
12 retinopathy/maculopathy was now the second leading cause of blindness certification. This difference was
13 statistically significant (P=0.009). In contrast, hereditary retinal disorders which were the second leading
14 cause of blindness certification in 1999-2000 accounting for 258 cases (15.8% of total), had increased to
15 354 cases (20.2%) by 2009-2010 and have now become the leading cause of certifiable blindness in the
16 working age group in England and Wales. Optic atrophy remained the third leading cause in 1999-2000 and
17 2009-2010 with an increase from 165 cases (10.1%) to 248 cases (14.1%) respectively. A notable finding
18 was that degeneration of the macula and posterior pole, which accounted for 7.7% of blindness registration
19 in 1999-2000, had dropped in percentage terms and now accounted for only 3.0% by 2009-2010. Other
20 causes of blindness registration remained roughly similar for the two time periods.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 Discussion

39 This report provides updated estimates on the causes of certifiable blindness in England and Wales in
40 working age adults. Three main diseases were responsible for half of all certifications – hereditary retinal
41 disorders (20.2%), diabetic retinopathy/maculopathy (14.4%) and optic atrophy (14.1%). A marked change
42 has occurred in the relative importance of these main causes of blindness certifications since the last major
43 analysis in 1999-2000,⁶ with diabetic retinopathy/maculopathy now no longer the leading cause of
44 blindness in working age adults. Since at least 1963,⁹ diabetic retinopathy/maculopathy has been the
45 leading cause of blindness among working age adults in England and Wales; a similar situation exists in
46 other developed countries such as the United States.¹⁰ Over the past decade the proportion of
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 certifications for hereditary retinal disorders has slowly risen,⁸ while that for diabetic
3
4 retinopathy/maculopathy has reduced, resulting in the two conditions swapping rankings.

5
6
7
8 This report is not designed to identify the reasons behind these changes or estimate the incidence of
9
10 blindness from diabetes. The prevalence of diabetes in the UK is not known with certainty, with several
11
12 limited general practice surveys suggesting a range of between 1-2% of the general population¹¹⁻¹⁴; we are
13
14 thus not able to estimate the incidence of blindness from diabetes. Nonetheless, available data suggest the
15
16 prevalence of diabetes in England and Wales has increased over the period in question^{11;13}, which would be
17
18 expected to lead to increased rates of blindness if other factors remained constant. In this context we
19
20 speculate that several intervening public health developments may have contributed to the reduction in
21
22 both absolute and proportional rates of registrable blindness from diabetes amongst working age adults.
23
24 Between 2003-2008 both England and Wales introduced nationwide diabetic retinopathy screening
25
26 services with the aim of reducing the incidence of blindness from diabetic eye disease. These are known as
27
28 the NHS Diabetic Eye Screening Program (England)¹⁵ and Diabetic Retinopathy Screening Service Wales
29
30 (DRSSW)¹⁶, and these programmes annually screen almost 2 million and 150,000 patients with diabetes,
31
32 respectively. Concurrent with these screening programmes, in 2004 the Quality and Outcomes
33
34 Framework¹⁷ was introduced to incentivise general practitioners in the United Kingdom to improve primary
35
36 care management of several conditions including diabetes. Several studies have documented an
37
38 improvement in the quality of care for diabetes since this was introduced,^{18;19} and the effort may have
39
40 contributed to the improvement in glycaemic control documented since the late 1990s.^{17;20} The decline in
41
42 both the absolute number and relative proportion of blindness certifications due to diabetic
43
44 retinopathy/maculopathy amongst working age adults since introduction of these public health measures
45
46 may be an indicator of their effectiveness. Nonetheless this remains speculative at present, and such
47
48 explanations should be read with caution.
49
50
51
52
53
54

55
56 Whether increased numbers of certification for inherited eye diseases reflects improved certification of
57
58 existing sight impairment, or a true increase in incidence of these disorders is unclear. The progress made
59
60

1 over the last decade in molecular genetics/diagnostics and the increasing avenues of research/clinical trials
2
3 for inherited retinal disease with widespread media coverage may plausibly have resulted in higher
4
5 community awareness and increased clinic visits and thereby registration,⁴ without a true increase in
6
7 incidence rates. An observation in favour of this scenario is that the numbers of blindness certification for
8
9 optic atrophy have also increased over the last decade, in tandem with those for inherited retinal disease,
10
11 while those for other non-inherited conditions such as glaucoma have remained fairly constant. Hereditary
12
13 retinal diseases occur more frequently in communities with a higher rate of consanguinity, and it is
14
15 conceivable that increased rates of immigration from countries where consanguinity is more prevalent may
16
17 have contributed to these findings, though at this stage this remains speculative. Another possibility is that
18
19 diagnostic transfer or misclassification may have occurred, for example where some cases of hereditary
20
21 retinal disorders may have been mislabeled as 'degeneration of macula and posterior pole'. In order to
22
23 explain the increase in hereditary retinal disorders, this would have had to occur preferentially in 1999-
24
25 2000 versus 2009-2010. However, misclassification of diabetic retinopathy/maculopathy as hereditary
26
27 retinal disorders is unlikely to occur given how different the conditions are, and so would not explain the
28
29 absolute reduction in the number of certifications for blindness due to diabetes.
30
31
32
33
34
35
36
37
38
39

40 These findings have implications for clinical care and research budget allocation. A prolonged focus on
41
42 prevention and treatment of diabetic eye disease has likely contributed to the decline in blindness
43
44 certifications from this disorder amongst working age adults, and the rate is expected to decline further
45
46 with the recent National Institute for Clinical Excellence (NICE) approval of ranibizumab for treatment of
47
48 diabetic maculopathy. Now that hereditary retinal diseases comprise the leading cause of blindness
49
50 certifications in working age adults, an increased focus on clinical management of these conditions (e.g.
51
52 with low vision aids, visual rehabilitation) and greater allocation of research funding to study these
53
54 disorders may be appropriate. Funding bodies may need to re-asses their funding priorities.
55
56
57

58 **Strengths and Limitations**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Data from BD8 and CVI registrations represent some of the best available epidemiological data on sight impairment in England and Wales and is regarded as a major public health indicator.⁵ Strengths of the data include nationwide coverage, collection of uniform data fields with pre-specified tick boxes, and clear and consistent definitions of sight impairment.

Limitations that should be highlighted include that fact that blindness certifications are not equivalent to blindness rates. This has been discussed previously^{3,4} and it is estimated that up to 53% of eligible patients may not be registered blind despite consultation with an ophthalmologist.⁷ However, arguments have been advanced that in time, most patients eligible to be registered will in fact do so,⁷ and studies have shown a major increase in registration rates with increasing clinic visits.⁴

Another caveat to these results is that some patients who are certified blind may not always satisfy all of the official criteria, with one study suggesting an inappropriate blindness certification rate of 23%.³ Such inappropriate certifications may inflate the numbers somewhat but it should be borne in mind that the aim of certification is not to identify persons meeting rigid clinical criteria but to identify and count those with significant visual impairment who may benefit from state assistance. Indeed, current guidelines for completion of CVI forms state that the criteria should be interpreted in the context of the patient's functional status rather than as strict cut-offs. Another precaution when interpreting these results is that the figures for the two time periods were collated from different forms. The differences in these forms are discussed elsewhere⁷ and one of the main complications in comparing temporal trends is the increase in the number of forms where a main cause has not been identified. In the 1999-2000 dataset, which was derived from BD8, approximately 4% of forms had 'multiple pathology'; in the 2009-2010 dataset derived from CVI, this had increased to 14%. This raised the possibility that diabetic retinopathy/maculopathy may have been under-reported for the 2009-2010 period. We attempted to address this by examining the contributory causes in those without a main cause recorded and using these in place of the missing main cause; this analysis resulted in only small changes to the percentage of blindness due to each cause and did not change the overall ranking of the top six causes. This suggests that the rate of under-reporting of main

1 causes was similar for most categories and not responsible for the shift in the leading causes of blindness
2
3 certifications.
4
5
6
7

8 In summary, this report found three main causes were responsible for half of all blindness certifications
9
10 among working age adults in England and Wales from 2009-2010 - hereditary retinal disorders (20.2%),
11
12 followed by diabetic retinopathy/maculopathy (14.4%) and optic atrophy (14.1%). This marks the first time
13
14 in almost five decades that diabetic retinopathy/maculopathy is no longer the leading cause of blindness in
15
16 working age adults, and may be related to the introduction of nationwide public health measures in
17
18 England and Wales. The results have implications for resource allocations for clinical care delivery and
19
20 research.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Numbers of working age adults (age 16-64) with severe sight impairment (blindness) in England and Wales: certifications 2009-2010. The 'Main cause' column lists the number of certifications with the corresponding diagnosis; the 'Contributory cause' column lists the contributory causes in certifications from the 'Multiple pathology' and 'No Information on main cause' categories.

ICD-9 Codes	Diagnosis	Main cause (% Total)	Contributory cause (% Total)	Combined (% Total)
362.7	Hereditary retinal disorders	354 (20.2)	29 (6.6)	383 (20.0)
362/34000	Diabetic retinopathy/maculopathy	253 (14.4)	56 (12.8)	309 (16.2)
377.1	Optic atrophy	248 (14.1)	46 (10.5)	294 (15.4)
365	Glaucoma	104 (5.9)	60 (13.7)	164 (8.6)
743-760	Congenital abnormalities of the eye	89 (5.1)	32 (7.3)	121 (6.3)
377.7	Disorders of visual cortex	72 (4.1)	24 (5.5)	96 (5.0)
430-438	Cerebrovascular disease	56 (3.2)	21 (4.8)	77 (4.0)
362.5	Degeneration of macula and posterior pole	52 (3.0)	14 (3.2)	66 (3.5)
360.2	Myopiap	49 (2.8)	23 (5.2)	72 (3.8)
370-371	Corneal disorders	45 (2.6)	34 (7.7)	79 (4.1)
-	Multiple pathology	242 (13.8)	-	-
-	Other conditions	150 (8.5)	100 (22.8)	250 (13.1)
-	No information on main cause	42 (2.4)	-	-
Total		1756	439*	1911*

ICD refers to International Classification of Disease.

*Including contributory causes. The total number of contributory causes is greater than the sum of 'Multiple pathology' and 'No information on main cause' categories because persons can have between one and four contributory causes documented.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1. Main causes of severe sight impairment (blindness) in England and Wales in working age adults (age 16-64): certifications 2009-2010.

Figure 2. 10-year change in causes of severe sight impairment (blindness) in England and Wales in working age adults (age 16-64): certifications 1999-2000 and 2009-2010.

For peer review only

Sources of Funding:

This study was supported by grants from the RNIB and the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The data captured by CVI are DH copyright and this work was made possible by collaboration with the Royal College of Ophthalmologists. The views expressed in this report are those of the authors and do not necessarily reflect those of the funding bodies. MM is a recipient of a Foundation Fighting Blindness Career Development Award.

Contributorship Statement:

All authors (GL, MM, CB) have contributed to 1) conception and design, acquisition of data, and analysis and interpretation of data; 2) drafting the article and revising it critically for important intellectual content; and 3) given final approval of the version to be published.

Financial Disclosure(s):

The authors have no proprietary or commercial interest in any materials discussed in this article.

Conflict of interest:

The authors have read and understood the BMJ Group policy on declaration of interests and declare no conflict of interest. All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that (1) No authors had support from any commercial companies for the submitted work; (2) GL received a fellowship from the Royal Australia New Zealand College of Ophthalmologists (RANZCO) Eye Foundation/Novartis scholarship for unrelated work during the period this report was written. No other authors have relationships with any companies that might have an interest in the submitted work in the previous 3 years; (3) No authors, their spouses, partners, or children have financial relationships that may be relevant to the submitted work; and (4) No authors have no non-financial interests that may be relevant to the submitted work.

Data sharing:

Technical appendix, statistical code, and dataset available from the corresponding author or at Dryad repository, who will provide a permanent, citable and open access home for the dataset.

Licensing

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

Reference List

- 1
2
3
4 (1) Sorsby A. The causes of blindness in England 1948-50. 1953. London, HMSO.
- 5
6 (2) Sorsby A. The incidence and causes of blindness in England and Wales 1948-1962. 1-78. 1966.
7 London, HM Stationery Office. Reports on Public Health and Medical Subjects No. 114.
8
- 9
10 (3) Barry RJ, Murray PI. Unregistered visual impairment: is registration a failing system? Br J
11 Ophthalmol 2005; 89(8):995-998.
12
- 13 (4) Robinson R, Deutsch J, Jones HS, et al. Unrecognised and unregistered visual impairment. Br J
14 Ophthalmol 1994; 78(10):736-740.
15
- 16 (5) UK Department of Health. Healthy Lives, Healthy People: Improving Outcomes and Supporting
17 Transparency. 2012.
18
- 19
20 (6) Bunce C, Wormald R. Causes of blind certifications in England and Wales: April 1999-March 2000.
21 Eye (Lond) 2008; 22(7):905-911.
22
- 23 (7) Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England &
24 Wales. BMC Public Health 2006; 6:58.
25
- 26 (8) Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales:
27 April 2007-March 2008. Eye (Lond) 2010; 24(11):1692-1699.
28
- 29 (9) Sorsby A. The incidence and causes of blindness in England and Wales 1963-1968. 1972. London,
30 HM Stationary Office. DHSS reports on public health and medical subjects No 128.
31
- 32 (10) Centers for Disease Control and Prevention. http://www.cdc.gov/visionhealth/basic_information/eye_disorders.htm [2013 [cited 2013 July 20];
33
- 34 (11) Lusignan S, Sismanidis C, Carey IM, et al. Trends in the prevalence and management of diagnosed
35 type 2 diabetes 1994-2001 in England and Wales. BMC Fam Pract 2005; 6(1):13.
36
- 37 (12) Khunti K, Goyder E, Baker R. Collation and comparison of multi-practice audit data: prevalence and
38 treatment of known diabetes mellitus. Br J Gen Pract 1999; 49(442):375-379.
39
- 40 (13) Holman N, Forouhi NG, Goyder E, et al. The Association of Public Health Observatories (APHO)
41 Diabetes Prevalence Model: estimates of total diabetes prevalence for England, 2010-2030. Diabet
42 Med 2011; 28(5):575-582.
43
- 44 (14) Forouhi NG, Merrick D, Goyder E, et al. Diabetes prevalence in England, 2001--estimates from an
45 epidemiological model. Diabet Med 2006; 23(2):189-197.
46
- 47 (15) NHS Diabetic Eye Screening Programme. <http://diabeticeye.screening.nhs.uk/about> [2013
48
- 49 (16) Diabetic Retinopathy Screening Service Wales. <http://www.cardiffandvaleuhb.wales.nhs.uk/drssw> [
50 2013
51
- 52 (17) Calvert M, Shankar A, McManus RJ, et al. Effect of the quality and outcomes framework on diabetes
53 care in the United Kingdom: retrospective cohort study. BMJ 2009; 338:b1870.
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (18) Campbell SM, Reeves D, Kontopantelis E, et al. Effects of pay for performance on the quality of primary care in England. *N Engl J Med* 2009; 361(4):368-378.
- (19) Millett C, Saxena S, Ng A, et al. Socio-economic status, ethnicity and diabetes management: an analysis of time trends using the health survey for England. *J Public Health (Oxf)* 2007; 29(4):413-419.
- (20) Oluwatowoju I, Abu E, Wild SH, et al. Improvements in glycaemic control and cholesterol concentrations associated with the Quality and Outcomes Framework: a regional 2-year audit of diabetes care in the UK. *Diabet Med* 2010; 27(3):354-359.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Changes in the Leading Causes of Blind Certifications in Working Age Adults in England and Wales 2009/2010 versus 1999/2000

– With Diabetic Retinopathy Now No Longer the Leading Cause.

Short title: Blindness in England and Wales 2009/2010

Gerald Liew, Michel Michaelides*, Catey Bunce*

Moorfields Eye Hospital NHS Foundation Trust, London. EC1V 2PD, UK.

Gerald Liew, Medical Retina Research Fellow;

Michel Michaelides, Consultant Ophthalmologist.

Centre for Vision Research, Westmead Millenium Institute, University of Sydney, Sydney, Australia.

Gerald Liew, Honorary Senior Lecturer

Department of Genetics, University College London, Institute of Ophthalmology, Bath Street, London EC1V 9EL, UK;

Michel Michaelides, Clinical Senior Lecturer

National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology.

Catey Bunce, Senior Statistician

*Both authors contributed equally to the work and should be considered joint senior and corresponding authors.

Financial Disclosure(s):

The authors have no proprietary or commercial interest in any materials discussed in this article.

Conflict of interest:

The authors have read and understood the BMJ Group policy on declaration of interests and declare no conflict of interest. All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that (1) No authors had support from any commercial companies for the submitted work; (2) GL received a fellowship from the Royal Australia New Zealand College of Ophthalmologists (RANZCO) Eye Foundation/Novartis scholarship for unrelated work during the period this report was written. No other authors have relationships with any companies that might have an interest in the submitted work in the previous 3 years; (3) No authors, their spouses, partners, or children have financial relationships that may be relevant to the submitted work; and (4) No authors have no non-financial interests that may be relevant to the submitted work.

Sources of Funding:

This study was supported by grants from the RNIB and the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The data captured by CVI are DH copyright and this work was made possible by collaboration with the Royal College of Ophthalmologists. The views expressed in this report are those of the authors and do not necessarily reflect those of the funding bodies. MM is a recipient of a Foundation Fighting Blindness Career Development Award.

Licensing

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

Corresponding authors:

C. Bunce, Research and Development, Moorfields Eye Hospital, City Road, London EC1V2PD, UK
Tel: +442075662820
Fax: +442086086925
Email: c.bunce@ucl.ac.uk

M. Michaelides, Department of Genetics, University College London, Institute of Ophthalmology, Bath Street, London EC1V 9EL, UK
Tel: +442076086864
Email: michel.michaelides@ucl.ac.uk

Word count: 2367

Abstract: 233

Abstract

Objectives. To report on the causes of blindness certifications in England and Wales in working age adults (16-64 years) in 2009-2010; and to compare these with figures from 1999-2000.

Design. Analysis of the national database of blindness certificates of vision impairment (CVIs) received by the Certifications Office.

Setting and Participants. Working age (16-64 years) population of England and Wales.

Main outcome measures. Number and cause of blindness certifications.

Results. The Certifications Office received 1756 CVIs for blindness from persons aged between 16 and 64 inclusive between 1st April 2009 to 31st March 2010. The main causes of blindness certifications were hereditary retinal disorders (354 certifications comprising 20.2% of the total), diabetic retinopathy/maculopathy (253 persons, 14.4%), and optic atrophy (248 persons, 14.1%). Together these three leading causes accounted for almost 50% of all blindness certifications. Between 1st April 1999 to 31st March 2000, the leading causes of blindness certification were diabetic retinopathy/maculopathy (17.7%), hereditary retinal disorders (15.8%) and optic atrophy (10.1%).

Conclusions. For the first time in at least five decades, diabetic retinopathy/maculopathy is no longer the leading cause of certifiable blindness amongst working age adults in England and Wales, having been overtaken by inherited retinal disorders. This change may be related to factors including the introduction of nationwide diabetic retinopathy screening programmes in England and Wales, and improved glycaemic control. Inherited retinal disease now representing the commonest cause of certification in the working age population has both clinical and research implications, including with respect to the provision of care/resources in the NHS and the allocation of research funding.

240 words

“Article Summary”

Article Focus.

- Blindness certifications are an important public health indicator in England and Wales.
- Every year, data on the number of persons certified blind is collected and the main causes listed.
- In 1999-2000, the leading causes of blindness certifications were diabetic retinopathy/maculopathy, hereditary retinal disorders and optic atrophy. We report results for 2009-2010.

Key messages.

- We report that for the first time in over five decades, diabetic retinopathy/maculopathy is no longer the leading cause of blindness in working age adults, having been overtaken by hereditary retinal disorders.
- This decline in blindness certifications from diabetic retinopathy/maculopathy may be related to the introduction of nationwide public health measures in England and Wales.
- The results have implications for resource allocations for clinical care delivery and research.

Strengths and Limitations

- Strengths of the data include nationwide coverage, collection of uniform data fields with pre-specified tick boxes, and clear and consistent definitions of sight impairment.
- Limitations include comparisons across two slightly different data collection forms.

Introduction

England and Wales have collected data on the number of blind people in the country since 1851.^{1,2} From 1930 until 2003, the causes of blindness have also been collected through use of a designated certificate, the BD8, which was completed by the examining ophthalmologist.² The BD8 was replaced in England in September 2005 by the Certificate of Vision Impairment (CVI), and in Wales in April 2007 by the equivalent form, the CVI-W. One copy of the CVI and CVI-W is then sent to the Certifications Office, London, for anonymised epidemiological analysis. The Certifications Office is currently funded by the RNIB (Royal National Institute for the Blind) and operates under the auspices of the Royal College of Ophthalmologists with CVI data under **Crown copyright, meaning the copyright is owned by the British Government.**

Although not compulsory, certification allows patients to be registered (i.e. placed on an official local council register) as either severely sight impaired (blind) or sight impaired (partially sighted), which then permits access to certain state benefits and social service provisions. There is hence an incentive for patients to be certified and counted, providing an estimate, albeit imperfect,^{3,4} of the causes and burden of blindness in England and Wales. The importance of these data is highlighted by the fact that certification figures have recently been adopted in 2012 as an indicator for preventable sight loss and included in the Public Health Outcomes Framework.⁵ In this report we present the findings from an analysis of working age blindness certifications from 2009-2010 and compare these with figures from 1999-2000.⁶ Major changes in leading causes of blindness certification in this age group have occurred over this period; subsequent publications will report on findings in persons of other age groups.

Methods

Details of data entry, collections and transmission have been reported previously.⁶⁻⁸ **Between 1st April 2009 to 31st March 2010** data were obtained from CVI forms, whereas **between 1st April 1999 to 31st March 2000,** data were obtained from BD8 forms. With regards to CVI forms, data were transcribed from these paper-based forms into a database at the Certification Office. Part C of the CVI form collects information on the

1 causes of visual loss and requires the completing ophthalmologist to select from a list of common
2
3 diagnoses. More than one cause of visual loss can be selected in which case the main cause should be
4
5 highlighted using either an asterisk or circle. Guidelines are provided to assist with this process when the
6
7 main cause is not evident. 'Multiple' causes are used where the ophthalmologist completing the form has
8
9 not indicated a single main cause. Possible reasons for this selection include differing causes in the two
10
11 eyes, or more than one cause within one eye and the ophthalmologist is unable to determine which
12
13 contributes the most to the visual loss. Causes for visual impairment were coded using International
14
15 Classification of Diseases (ICD)-9 codes and grouped into disease categories as in previous reports.⁶⁻⁸
16
17

18
19
20
21 For 1999-2000, data were extracted from paper based BD8 forms in a similar fashion.⁶ Part 5 of the BD8
22
23 form has 16 fields for medical information including one for the main cause of visual loss and five for each
24
25 eye for contributory causes. For records where the main cause was not filled, this field was imputed
26
27 wherever possible using an algorithm published previously.⁸ In short this algorithm brought forward as the
28
29 main cause the contributing cause if any were so listed; if more than one contributory cause was listed, the
30
31 patient was listed as having 'multiple causes'. The main difference between data collected from the CVI and
32
33 BD8 forms is the number of certifications with 'multiple causes' of visual impairment which was higher in
34
35 the CVI forms.⁷ We have previously minimized bias from this source by re-examining the certificates with
36
37 'multiple causes', extracting the contributory causes listed and tabulating them with the main causes.⁷ We
38
39 follow the same procedure in this report.
40
41
42
43
44

45 Blindness was defined according to criteria previously described on the BD8 and CVI forms as either best
46
47 corrected visual acuity in the better eye of either (1) worse than 3/60, or (2) worse than 6/60 with severely
48
49 constricted visual fields, or (3) better than 6/60 with severely constricted visual fields particularly the
50
51 inferior field.
52

53 54 55 56 **Analyses** 57 58 59 60

1 Data regarding the main cause of visual impairment were extracted from the forms and grouped into
2
3 disease categories as previously described.⁶⁻⁸ For CVI data, those with 'multiple causes' or 'no information
4
5 on main cause' of visual impairment had contributory causes extracted and listed, and later combined with
6
7 the main causes. Pie and bar charts were used to graphically illustrate the distribution of the main causes of
8
9 visual impairment. Proportions of blindness registrations due to each cause are presented rather than
10
11 adjusted incidence rates in order to indicate the relative contribution of each condition to the pool of vision
12
13 impairment. Currently almost every grant application for diabetic retinopathy projects commences with a
14
15 statement that diabetic retinopathy is the most common cause of visual loss in the working age population
16
17 – we present proportions of blindness registrations to determine if this statement remains valid. **X² tests**
18
19 **were performed to test differences in proportions.**
20
21
22
23
24

25 Results

26
27 For the period **1st April 2009 to 31st March 2010**, the Certifications Office received 1756 CVIs for blindness
28
29 from persons aged between 16 and 64 inclusive. This compares with 1637 BD8 forms for blindness received
30
31 between **1st April 1999 and 31st March 2000**, details of which have been reported previously.⁸ **Table 1**
32
33 shows the number of persons certified blind for each of the disease categories. Hereditary retinal
34
35 disorders, including Stargardt Disease and Retinitis Pigmentosa, formed the largest category with 354
36
37 certifications comprising 20.2% of the total. Diabetic retinopathy/maculopathy was the second largest
38
39 cause of certifiable blindness with 253 persons (14.4%), followed by optic atrophy with 248 persons
40
41 (14.1%). Together these 3 leading causes accounted for almost 50% of all blindness certifications in the
42
43 working age group. Glaucoma was responsible for 104 (5.9%) blindness certifications, followed by
44
45 congenital abnormalities of the eye which included congenital cataracts and retinopathy of prematurity (89
46
47 certifications, 5.1%). Multiple pathologies were listed for 242 persons (13.8%) and no information on the
48
49 main cause was listed for 42 persons (2.4%). When these categories were examined for contributory
50
51 causes, the most common contributory causes recorded were glaucoma (60 persons), diabetic
52
53 retinopathy/maculopathy (56 persons) and optic atrophy (46 persons). Combining the main and
54
55 contributory causes resulted in small changes in the overall proportion of certifications due to specific
56
57
58
59
60

1 causes, but did not change the relative rankings of the top six causes of blindness (**Table 1**). 'Other
2 conditions' comprised 150 certifications (8.5%) of which the most common were malignant neoplasms of
3 the brain and nervous system (27 persons, 1.5%) and retinal detachments (24 persons, 1.4%). **Figure 1**
4 shows the distribution of the causes of blindness certifications graphically in a pie chart.
5
6
7
8
9

10
11
12 We next compared the main causes of blindness certifications from 1999-2000 (n=1637) with the figures
13 above from 2009-2010 (n=1756). The results are shown graphically in **Figure 2**. From 1999-2000, the
14 leading cause of blindness certification was diabetic retinopathy/maculopathy which accounted for 290
15 certifications (17.7%). By 2009-2010, this figure had decreased to 253 (14.4%), and diabetic
16 retinopathy/maculopathy was now the second leading cause of blindness certification. **This difference was**
17 **statistically significant (P=0.009)**. In contrast, hereditary retinal disorders which were the second leading
18 cause of blindness certification in 1999-2000 accounting for 258 cases (15.8% of total), had increased to
19 354 cases (20.2%) by 2009-2010 and have now become the leading cause of certifiable blindness in the
20 working age group in England and Wales. Optic atrophy remained the third leading cause in 1999-2000 and
21 2009-2010 with an increase from 165 cases (10.1%) to 248 cases (14.1%) respectively. A notable finding
22 was that degeneration of the macula and posterior pole, which accounted for 7.7% of blindness registration
23 in 1999-2000, had dropped in percentage terms and now accounted for only 3.0% by 2009-2010. Other
24 causes of blindness registration remained roughly similar for the two time periods.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 Discussion

44 This report provides updated estimates on the causes of certifiable blindness in England and Wales in
45 working age adults. Three main diseases were responsible for half of all certifications – hereditary retinal
46 disorders (20.2%), diabetic retinopathy/maculopathy (14.4%) and optic atrophy (14.1%). A marked change
47 has occurred in the relative importance of these main causes of blindness certifications since the last major
48 analysis in 1999-2000,⁶ with diabetic retinopathy/maculopathy now no longer the leading cause of
49 blindness in working age adults. Since at least 1963,⁹ diabetic retinopathy/maculopathy has been the
50 leading cause of blindness among working age adults in England and Wales; a similar situation exists in
51
52
53
54
55
56
57
58
59
60

1 other developed countries such as the United States.¹⁰ Over the past decade the proportion of
2
3
4 certifications for hereditary retinal disorders has slowly risen,⁸ while that for diabetic
5
6 retinopathy/maculopathy has reduced, resulting in the two conditions swapping rankings.
7
8
9

10 This report is not designed to identify the reasons behind these changes or estimate the incidence of
11
12 blindness from diabetes. The prevalence of diabetes in the UK is not known with certainty, with several
13
14 limited general practice surveys suggesting a range of between 1-2% of the general population¹¹⁻¹⁴; we are
15
16 thus not able to estimate the incidence of blindness from diabetes. Nonetheless, available data suggest the
17
18 prevalence of diabetes in England and Wales has increased over the period in question^{11;13}, which would be
19
20 expected to lead to increased rates of blindness if other factors remained constant. In this context we
21
22 speculate that several intervening public health developments may have contributed to the reduction in
23
24 both absolute and proportional rates of registrable blindness from diabetes amongst working age adults.
25
26

27 Between 2003-2008 both England and Wales introduced nationwide diabetic retinopathy screening
28
29 services with the aim of reducing the incidence of blindness from diabetic eye disease. These are known as
30
31 the NHS Diabetic Eye Screening Program (England)¹⁵ and Diabetic Retinopathy Screening Service Wales
32
33 (DRSSW)¹⁶, and these programmes annually screen almost 2 million and 150,000 patients with diabetes,
34
35 respectively. Concurrent with these screening programmes, in 2004 the Quality and Outcomes
36
37 Framework¹⁷ was introduced to incentivise general practitioners in the United Kingdom to improve primary
38
39 care management of several conditions including diabetes. Several studies have documented an
40
41 improvement in the quality of care for diabetes since this was introduced,^{18;19} and the effort may have
42
43 contributed to the improvement in glycaemic control documented since the late 1990s.^{17;20} The decline in
44
45 both the absolute number and relative proportion of blindness certifications due to diabetic
46
47 retinopathy/maculopathy amongst working age adults since introduction of these public health measures
48
49 may be an indicator of their effectiveness. Nonetheless this remains speculative at present, and such
50
51 explanations should be read with caution.
52
53
54
55
56
57
58
59
60

1
2 Whether increased numbers of certification for inherited eye diseases reflects improved certification of
3
4 existing sight impairment, or a true increase in incidence of these disorders is unclear. The progress made
5
6 over the last decade in molecular genetics/diagnostics and the increasing avenues of research/clinical trials
7
8 for inherited retinal disease with widespread media coverage may plausibly have resulted in higher
9
10 community awareness and increased clinic visits and thereby registration,⁴ without a true increase in
11
12 incidence rates. An observation in favour of this scenario is that the numbers of blindness certification for
13
14 optic atrophy have also increased over the last decade, in tandem with those for inherited retinal disease,
15
16 while those for other non-inherited conditions such as glaucoma have remained fairly constant. Hereditary
17
18 retinal diseases occur more frequently in communities with a higher rate of consanguinity, and it is
19
20 conceivable that increased rates of immigration from countries where consanguinity is more prevalent may
21
22 have contributed to these findings, though at this stage this remains speculative. Another possibility is that
23
24 diagnostic transfer or misclassification may have occurred, for example where some cases of hereditary
25
26 retinal disorders may have been mislabeled as 'degeneration of macula and posterior pole'. In order to
27
28 explain the increase in hereditary retinal disorders, this would have had to occur preferentially in 1999-
29
30 2000 versus 2009-2010. However, misclassification of diabetic retinopathy/maculopathy as hereditary
31
32 retinal disorders is unlikely to occur given how different the conditions are, and so would not explain the
33
34 absolute reduction in the number of certifications for blindness due to diabetes.
35
36
37
38
39
40
41
42

43 These findings have implications for clinical care and research budget allocation. A prolonged focus on
44
45 prevention and treatment of diabetic eye disease has likely contributed to the decline in blindness
46
47 certifications from this disorder amongst working age adults, and the rate is expected to decline further
48
49 with the recent National Institute for Clinical Excellence (NICE) approval of ranibizumab for treatment of
50
51 diabetic maculopathy. Now that hereditary retinal diseases comprise the leading cause of blindness
52
53 certifications in working age adults, an increased focus on clinical management of these conditions (e.g.
54
55 with low vision aids, visual rehabilitation) and greater allocation of research funding to study these
56
57 disorders may be appropriate. Funding bodies may need to re-asses their funding priorities.
58
59
60

Strengths and Limitations

Data from BD8 and CVI registrations represent some of the best available epidemiological data on sight impairment in England and Wales and is regarded as a major public health indicator.⁵ Strengths of the data include nationwide coverage, collection of uniform data fields with pre-specified tick boxes, and clear and consistent definitions of sight impairment.

Limitations that should be highlighted include that fact that blindness certifications are not equivalent to blindness rates. This has been discussed previously^{3,4} and it is estimated that up to 53% of eligible patients may not be registered blind despite consultation with an ophthalmologist.⁷ However, arguments have been advanced that in time, most patients eligible to be registered will in fact do so,⁷ and studies have shown a major increase in registration rates with increasing clinic visits.⁴

Another caveat to these results is that some patients who are certified blind may not always satisfy all of the official criteria, with one study suggesting an inappropriate blindness certification rate of 23%.³ Such inappropriate certifications may inflate the numbers somewhat but it should be borne in mind that the aim of certification is not to identify persons meeting rigid clinical criteria but to identify and count those with significant visual impairment who may benefit from state assistance. Indeed, current guidelines for completion of CVI forms state that the criteria should be interpreted in the context of the patient's functional status rather than as strict cut-offs. Another precaution when interpreting these results is that the figures for the two time periods were collated from different forms. The differences in these forms are discussed elsewhere⁷ and one of the main complications in comparing temporal trends is the increase in the number of forms where a main cause has not been identified. In the 1999-2000 dataset, which was derived from BD8, approximately 4% of forms had 'multiple pathology'; in the 2009-2010 dataset derived from CVI, this had increased to 14%. This raised the possibility that diabetic retinopathy/maculopathy may have been under-reported for the 2009-2010 period. We attempted to address this by examining the contributory causes in those without a main cause recorded and using these in place of the missing main

1
2 cause; this analysis resulted in only small changes to the percentage of blindness due to each cause and did
3
4 not change the overall ranking of the top six causes. This suggests that the rate of under-reporting of main
5
6 causes was similar for most categories and not responsible for the shift in the leading causes of blindness
7
8 certifications.
9

10
11
12 In summary, this report found three main causes were responsible for half of all blindness certifications
13
14 among working age adults in England and Wales from 2009-2010 - hereditary retinal disorders (20.2%),
15
16 followed by diabetic retinopathy/maculopathy (14.4%) and optic atrophy (14.1%). This marks the first time
17
18 in almost five decades that diabetic retinopathy/maculopathy is no longer the leading cause of blindness in
19
20 working age adults, and may be related to the introduction of nationwide public health measures in
21
22 England and Wales. The results have implications for resource allocations for clinical care delivery and
23
24 research.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Numbers of working age adults (age 16-64) with severe sight impairment (blindness) in England and Wales: certifications 2009-2010. The 'Main cause' column lists the number of certifications with the corresponding diagnosis; the 'Contributory cause' column lists the contributory causes in certifications from the 'Multiple pathology' and 'No Information on main cause' categories.

ICD-9 Codes	Diagnosis	Main cause (% Total)	Contributory cause (% Total)	Combined (% Total)
362.7	Hereditary retinal disorders	354 (20.2)	29 (6.6)	383 (20.0)
362/34000	Diabetic retinopathy/maculopathy	253 (14.4)	56 (12.8)	309 (16.2)
377.1	Optic atrophy	248 (14.1)	46 (10.5)	294 (15.4)
365	Glaucoma	104 (5.9)	60 (13.7)	164 (8.6)
743-760	Congenital abnormalities of the eye	89 (5.1)	32 (7.3)	121 (6.3)
377.7	Disorders of visual cortex	72 (4.1)	24 (5.5)	96 (5.0)
430-438	Cerebrovascular disease	56 (3.2)	21 (4.8)	77 (4.0)
362.5	Degeneration of macula and posterior pole	52 (3.0)	14 (3.2)	66 (3.5)
360.2	Myopia	49 (2.8)	23 (5.2)	72 (3.8)
370-371	Corneal disorders	45 (2.6)	34 (7.7)	79 (4.1)
-	Multiple pathology	242 (13.8)	-	-
-	Other conditions	150 (8.5)	100 (22.8)	250 (13.1)
-	No information on main cause	42 (2.4)	-	-
Total		1756	439*	1911*

ICD refers to International Classification of Disease.

*Including contributory causes. The total number of contributory causes is greater than the sum of 'Multiple pathology' and 'No information on main cause' categories because persons can have between one and four contributory causes documented.

Figure 1. Main causes of severe sight impairment (blindness) in England and Wales in working age adults (age 16-64): certifications 2009-2010.





Figure 2. 10-year change in causes of severe sight impairment (blindness) in England and Wales in working age adults (age 16-64): certifications 1999-2000 and 2009-2010.




Reference List

- 1
2
3
4
5 (1) Sorsby A. The causes of blindness in England 1948-50. 1953. London, HMSO.
- 6
7 (2) Sorsby A. The incidence and causes of blindness in England and Wales 1948-1962. 1-78. 1966.
- 8 London, HM Stationery Office. Reports on Public Health and Medical Subjects No. 114.
- 9
- 10
11 (3) Barry RJ, Murray PI. Unregistered visual impairment: is registration a failing system? Br J
- 12 Ophthalmol 2005; 89(8):995-998.
- 13
- 14 (4) Robinson R, Deutsch J, Jones HS, Youngson-Reilly S, Hamlin DM, Dhurjon L et al. Unrecognised and
- 15 unregistered visual impairment. Br J Ophthalmol 1994; 78(10):736-740.
- 16
- 17 (5) UK Department of Health. Healthy Lives, Healthy People: Improving Outcomes and Supporting
- 18 Transparency. 2012.
- 19
- 20
21 (6) Bunce C, Wormald R. Causes of blind certifications in England and Wales: April 1999-March 2000.
- 22 Eye (Lond) 2008; 22(7):905-911.
- 23
- 24 (7) Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England &
- 25 Wales. BMC Public Health 2006; 6:58.
- 26
- 27 (8) Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales:
- 28 April 2007-March 2008. Eye (Lond) 2010; 24(11):1692-1699.
- 29
- 30 (9) Sorsby A. The incidence and causes of blindness in England and Wales 1963-1968. 1972. London,
- 31 HM Stationary Office. DHSS reports on public health and medical subjects No 128.
- 32
- 33 (10) Centers for Disease Control and Prevention. http://www.cdc.gov/visionhealth/basic_information/eye_disorders.htm [2013 [cited 2013 July 20];
- 34
- 35 (11) Lusignan S, Sismanidis C, Carey IM, DeWilde S, Richards N, Cook DG. Trends in the prevalence and
- 36 management of diagnosed type 2 diabetes 1994-2001 in England and Wales. BMC Fam Pract 2005;
- 37 6(1):13.
- 38
- 39 (12) Khunti K, Goyder E, Baker R. Collation and comparison of multi-practice audit data: prevalence and
- 40 treatment of known diabetes mellitus. Br J Gen Pract 1999; 49(442):375-379.
- 41
- 42 (13) Holman N, Forouhi NG, Goyder E, Wild SH. The Association of Public Health Observatories (APHO)
- 43 Diabetes Prevalence Model: estimates of total diabetes prevalence for England, 2010-2030. Diabet
- 44 Med 2011; 28(5):575-582.
- 45
- 46 (14) Forouhi NG, Merrick D, Goyder E, Ferguson BA, Abbas J, Lachowycz K et al. Diabetes prevalence in
- 47 England, 2001--estimates from an epidemiological model. Diabet Med 2006; 23(2):189-197.
- 48
- 49 (15) NHS Diabetic Eye Screening Programme. <http://diabeticeye.screening.nhs.uk/about> [2013
- 50
- 51 (16) Diabetic Retinopathy Screening Service Wales. <http://www.cardiffandvaleuhb.wales.nhs.uk/drssw> [
- 52 2013
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (17) Calvert M, Shankar A, McManus RJ, Lester H, Freemantle N. Effect of the quality and outcomes framework on diabetes care in the United Kingdom: retrospective cohort study. *BMJ* 2009; 338:b1870.
- (18) Campbell SM, Reeves D, Kontopantelis E, Sibbald B, Roland M. Effects of pay for performance on the quality of primary care in England. *N Engl J Med* 2009; 361(4):368-378.
- (19) Millett C, Saxena S, Ng A, Mainous A, III, Majeed A. Socio-economic status, ethnicity and diabetes management: an analysis of time trends using the health survey for England. *J Public Health (Oxf)* 2007; 29(4):413-419.
- (20) Oluwatowaju I, Abu E, Wild SH, Byrne CD. Improvements in glycaemic control and cholesterol concentrations associated with the Quality and Outcomes Framework: a regional 2-year audit of diabetes care in the UK. *Diabet Med* 2010; 27(3):354-359.

**Main Causes of Severe Sight Impairment
(Blindness) Certifications 2009-10
Age 16-64 years**




90x109mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Change in Main Causes of Blindness Certification from 2000 to 2010



106x90mm (300 x 300 DPI)

For peer review only

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract Y	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale Y	2	Explain the scientific background and rationale for the investigation being reported
Objectives Y	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design Y	4	Present key elements of study design early in the paper
Setting Y	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants Y	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables Y	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement Y	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias Y	9	Describe any efforts to address potential sources of bias
Study size NA	10	Explain how the study size was arrived at
Quantitative variables NA	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods Y	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(e) Describe any sensitivity analyses

Continued on next page

For peer review only

Results

Participants Y	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data Y	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data Y	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results Y	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses Y	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results Y	18	Summarise key results with reference to study objectives
Limitations Y	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation Y	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability Y	21	Discuss the generalisability (external validity) of the study results

Other information

Funding Y	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
--------------	----	---

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.